AZD2171 in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Last Modified: 4/6/2009 First Published: 3/24/2006
Alternate Title
Phase II Study of AZD2171 in Patients With Malignant Pleural, Peritoneal, or Tunica Vaginalis Mesothelioma That is Not Amenable to Curative Surgery
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase II | Biomarker/Laboratory analysis, Treatment | Active | 18 and over | UCCRC-14203B NCI-7103, 7103, NCT00309946 |
Trial Description
Purpose:
AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.
Eligibility:
Eligibility criteria include the following:
Final eligibility for a clinical trial is determined by the health professionals conducting the trial.
Treatment/Intervention:
Patients will receive ADZ2171 by mouth once a day. Treatment may continue for as long as benefit is shown. Blood will be collected periodically for laboratory studies.
After finishing treatment, patients will be evaluated for up to 8 weeks.
Important:
For more details about this trial, refer to the Health Professional version 6 of the trial summary.
If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site 7.
Trial Contact Information
Trial Lead Organizations
University of Chicago Cancer Research Center
 |  |  |
| Hedy Kindler, MD, Principal investigator |  | | Ph: 773-702-0360; 888-824-0200 |
|
 |
Trial Sites
 |  |  |  |
| U.S.A. |
 |
| California |
 |
| | Beverly Hills |
 |
| |
| |
| |
| | Tower Cancer Research Foundation |
| |
| | Philomena McAndrew, MD | |
| |
| | Duarte |
 |
| |
| | City of Hope Comprehensive Cancer Center |
| |
| | Clinical Trials Office - City of Hope Comprehensive Cancer Center | |
| | Email: becomingapatient@coh.org |
| |
| | Los Angeles |
 |
| |
| | USC/Norris Comprehensive Cancer Center and Hospital |
| |
| | Clinical Trials Office - USC/Norris Comprehensive Cancer Center and Hospital | |
| |
| | Martinez |
 |
| |
| | Contra Costa Regional Medical Center |
| |
| | Sharon Hiner, MD | | Ph: | 925-370-5114 | | | 800-232-4636 |
|
| | Email: shiner@hsd.co.contra-costa.ca.us |
| |
| | Pasadena |
 |
| |
| | City of Hope Medical Group |
| |
| | Mark McNamara, MD | |
| | Email: mmcnamara@ccsmg.com |
| |
| | Sacramento |
 |
| |
| | University of California Davis Cancer Center |
| |
| | Clinical Trials Office - University of California Davis Cancer Center | |
| |
| Illinois |
 |
| | Chicago |
 |
| |
| |
| | University of Chicago Cancer Research Center |
| |
| | Clinical Trials Office - University of Chicago Cancer Research Center | |
| |
| | Decatur |
 |
| |
| | Decatur Memorial Hospital Cancer Care Institute |
| |
| | Clinical Trials Office - Decatur Memorial Hospital Cancer Care Institute | |
| |
| | Evanston |
 |
| |
| | Evanston Hospital |
| |
| | Clinical Trials Office - Evanston Hospital | |
| |
| | Harvey |
 |
| |
| | Ingalls Cancer Care Center at Ingalls Memorial Hospital |
| |
| | Clinical Trials Office - Ingalls Cancer Care Center at Ingalls Memorial Hospital | |
| |
| | Maywood |
 |
| |
| | Cardinal Bernardin Cancer Center at Loyola University Medical Center |
| |
| | Clinical Trials Office - Cardinal Bernardin Cancer Center | |
| |
| | Peoria |
 |
| |
| | Oncology Hematology Associates of Central Illinois, PC - Peoria |
| |
| | Sachdev Thomas, MD | |
| | Email: sthomas@ohaci.com |
| |
| | Springfield |
 |
| |
| | Central Illinois Hematology Oncology Center |
| |
| | Edem Agamah, MD, MS | |
| | Email: ihdn@aol.com |
| |
| Indiana |
 |
| | Fort Wayne |
 |
| |
| |
| | Fort Wayne Medical Oncology and Hematology |
| |
| | David Sciortino, MD | | Ph: | 260-484-8830 | | | 800-852-2333 |
|
| |
| | South Bend |
 |
| |
| | CCOP - Northern Indiana CR Consortium |
| |
| | David Taber, MD | | Ph: | 574-647-3353 | | | 800-284-7370 |
|
| |
| Michigan |
 |
| | Saint Joseph |
 |
| |
| |
| | Oncology Care Associates, PLLC |
| |
| | Eric Lester, MD | |
| |
| Pennsylvania |
 |
| | Hershey |
 |
| |
| |
| | Penn State Cancer Institute at Milton S. Hershey Medical Center |
| |
| | Clinical Trials Office - Penn State Cancer Institute at Milton S. Hershey Medical Center | |
| | Email: CTO@hmc.psu.edu |
| |
| Wisconsin |
 |
| | Milwaukee |
 |
| |
| |
| | Medical College of Wisconsin Cancer Center |
| |
| | Clinical Trials Office - Medical College of Wisconsin Cancer Center | |
| |
| Canada |
 |
| Ontario |
 |
| | Toronto |
 |
| |
| |
| |
| | Princess Margaret Hospital |
| |
| | Natasha Leighl, MD, FRCPC | |
| |
| Registry Information |
 |
| Official Title | | Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma |
 |
| Trial Start Date | | 2005-12-05 |
 |
| Trial Completion Date | | 2006-10-01 (estimated) |
 |
| Registered in ClinicalTrials.gov | | NCT00309946 8 |
 |
| Date Submitted to PDQ | | 2005-12-09 |
 |
| Information Last Verified | | 2007-06-03 |
 |
| NCI Grant/Contract Number | | CM17102, CA14599 |
Glossary TermsAZD2171 A substance being studied in the treatment of some types of cancer. AZD2171 may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. Also called cediranib and Recentin. blood A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes. brain metastasis (...meh-TAS-tuh-sis) Cancer that has spread from the original (primary) tumor to the brain. cell (sel) The individual unit that makes up the tissues of the body. All living things are made up of one or more cells. chemotherapy (KEE-moh-THAYR-uh-pee) Treatment with drugs that kill cancer cells. eligibility criteria (EH-lih-jih-BIH-lih-tee kry-TEER-ee-uh) In clinical trials, requirements that must be met for an individual to be included in a study. These requirements help make sure that patients in a trial are similar to each other in terms of specific factors such as age, type and stage of cancer, general health, and previous treatment. When all participants meet the same eligibility criteria, it gives researchers greater confidence that results of the study are caused by the intervention being tested and not by other factors. enzyme (EN-zime) A protein that speeds up chemical reactions in the body. malignant mesothelioma (muh-LIG-nunt MEH-zoh-THEE-lee-OH-muh) A rare type of cancer in which malignant cells are found in the lining of the chest or abdomen. Exposure to airborne asbestos particles increases one's risk of developing malignant mesothelioma. measurable disease A tumor that can be accurately measured in size. This information can be used to judge response to treatment. phase II trial A study to test whether a new treatment has an anticancer effect (for example, whether it shrinks a tumor or improves blood test results) and whether it works against a certain type of cancer. radiation therapy (RAY-dee-AY-shun THAYR-uh-pee) The use of high-energy radiation from x-rays, gamma rays, neutrons, protons, and other sources to kill cancer cells and shrink tumors. Radiation may come from a machine outside the body (external-beam radiation therapy), or it may come from radioactive material placed in the body near cancer cells (internal radiation therapy). Systemic radiation therapy uses a radioactive substance, such as a radiolabeled monoclonal antibody, that travels in the blood to tissues throughout the body. Also called irradiation and radiotherapy. surgery (SER-juh-ree) A procedure to remove or repair a part of the body or to find out whether disease is present. An operation. tumor (TOO-mer) An abnormal mass of tissue that results when cells divide more than they should or do not die when they should. Tumors may be benign (not cancer), or malignant (cancer). Also called neoplasm. |
Table of Links
| 1 | http://www.cancer.gov/clinicaltrials/learning |
| 2 | http://www.cancer.gov/cancertopics/factsheet/Information/clinical-trials |
| 3 | http://www.cancer.gov/clinicaltrials/learning/questions-to-ask-about-participat ing |
| 4 | http://www.nlm.nih.gov/medlineplus/druginformation.html |
| 5 | http://www.cancer.gov/clinicaltrials/UCCRC-14203B#EntryCriteria_CDR0000463521 |
| 6 | http://www.cancer.gov/clinicaltrials/UCCRC-14203B |
| 7 | http://cancer.gov/clinicaltrials |
| 8 | http://clinicaltrials.gov/ct/show/NCT00309946 |